Table 1.
Demographic and Clinical Characteristics of Heart and Lung Transplant Recipients Who Completed a Two-Dose SARS-CoV-2 mRNA Vaccine Series
| Participant characteristics | Total | HT recipients | LT recipients |
|---|---|---|---|
| n = 237 | n = 134 | n = 103 | |
| Age, median (IQR) years | 62 (46-69) | 60 (44-69) | 63 (48-70) |
| Female sex, n (%)a | 127 (55) | 67 (51) | 60 (59) |
| Non-white, n (%)b | 19 (8) | 13 (10) | 6 (6) |
| Hispanic ethnicity, n (%)c | 7 (3) | 5 (4) | 2 (2) |
| BMI, median kg/m2 (IQR) | 25.6 (21.9-29.7) | 25.5 (22.3-29.9) | 25.7 (21.9-29.4) |
| Years since transplant, median (IQR) | 5.1 (2.5-11.0) | 5.5 (2.6-12.4) | 5.0 (2.0-9.4) |
| Maintenance immunosuppression, n (%)d | |||
| Tacrolimus | 203 (86) | 113 (84) | 90 (87) |
| Mycophenolate | 148 (62) | 84 (63) | 64 (62) |
| Corticosteroids | 134 (57) | 35 (26) | 99 (96) |
| Sirolimus | 32 (14) | 22(16) | 10 (10) |
| Cyclosporine | 19 (8) | 13 (10) | 6 (6) |
| Azathioprine | 19 (8) | 4 (3) | 15 (15) |
| Everolimus | 17 (7) | 12 (9) | 5 (5) |
| Belatacept | 2 (1) | 0 (0) | 2 (2) |
| Maintenance immunosuppression combination, n (%) | |||
| Tacrolimus, mycophenolate, prednisone | 66 (28) | 12 (9) | 54 (52) |
| Cyclosporine, mycophenolate, prednisone | 5 (2) | 2 (1) | 3 (3) |
| Tacrolimus, mycophenolate | 58 (24) | 57 (43) | 1 (1) |
| Cyclosporine, mycophenolate | 6 (3) | 6 (4) | 0 (0) |
| Tacrolimus, everolimus, prednisone | 8 (3) | 5 (4) | 3 (3) |
| Everolimus, cyclosporine | 2 (1) | 2 (1) | 0 (0) |
| Everolimus, mycophenolate | 1 (<1) | 1 (1) | 0 (0) |
| Cyclosporine, prednisone | 9 (4) | 3 (2) | 6 (6) |
| Tacrolimus, prednisone | 44 (19) | 13 (10) | 31 (30) |
| Tacrolimus, everolimus, mycophenolate, prednisone | 1 (<1) | 0 (0) | 1 (1) |
| Vaccine manufacturer, n (%) | |||
| BNT162b2 (Pfizer-BioNTech) | 126 (53) | 70 (52) | 56 (54) |
| mRNA-1273 (Moderna) | 111 (47) | 64 (48) | 47 (46) |
BMI, body mass index; HT, Heart transplant; IQR, interquartile range; LT, Lung transplant.
a
Missing data for 3 participants.
b
Missing data for 3 participants.
c
Missing data for 4 participants.
d
Not mutually exclusive.